Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting
Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010
Title: Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose: Many epidemiologic studies of systemic…Abstract Number: 2738 • 2014 ACR/ARHP Annual Meeting
Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
Background/Purpose: The voltage-gated potassium channel Kv1.3 is a novel target for the treatment of autoimmune disorders including psoriatic and rheumatic diseases. ShK-186 is an exquisitely specific,…Abstract Number: 962 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis
Background/Purpose To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis. Methods We performed an up to date…Abstract Number: 1826 • 2014 ACR/ARHP Annual Meeting
A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children
Background/Purpose Lupus Nephritis (LN) occurs in up to 80% of childhood-onset Systemic Lupus Erythematosus (cSLE) and it has a worse prognosis than adults. The current…Abstract Number: 963 • 2014 ACR/ARHP Annual Meeting
Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept
Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome…Abstract Number: 1672 • 2014 ACR/ARHP Annual Meeting
Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?
Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients…Abstract Number: 1667 • 2014 ACR/ARHP Annual Meeting
Probability of 3 and 6 Month Complete Response in Lupus Nephritis
Background/Purpose: Lupus nephritis is a major cause of morbidity and mortality. The complete response rate is the most sensitive in detecting differences among therapeutic regimens.…Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting
The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…Abstract Number: 1654 • 2014 ACR/ARHP Annual Meeting
Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features
Background/Purpose: To assess acute thrombotic microangiopathy (aTMA) and chronic vascular lesions (cTMA) in lupus nephropathy and to evaluate their association with extrarrenal lupus features, antiphospholipid…Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting
High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis
Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…Abstract Number: 1648 • 2014 ACR/ARHP Annual Meeting
Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus (SLE), and the occurrence of LN is considered to be a…Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…Abstract Number: 1611 • 2014 ACR/ARHP Annual Meeting
Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Background/Purpose: Lupus nephritis (LN) is a serious complication of SLE. Reliable biomarkers to assess and/or predict renal involvement in SLE patients are needed. The aim…Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting
Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- Next Page »